Human immunodeficiency virus type 1 (HIV-1) envelope vaccines can now be evaluated for efficacy in macaques by challenging with chimeric viruses in which the env, tat and rev genes of simian immunodeficiency virus (SIV) have been replaced by those of HIV-1. Most experiments have so far been conducted using gp120 molecules derived from T-celladapted LAI or MN strains of HIV-1, which predominantly use the CXCR-4 co-receptor. These vaccines protect against infection by apathogenic chimeric virus carrying the same envelope sequences. In the experiment described here, four macaques were vaccinated with W61D gp120 derived from a low passage Dutch isolate and capable
Introduction
Simian immunodeficiency virus (SIV) infection of macaques is widely accepted as the most versatile model in which pathogenesis and prevention of lentivirus infection can be studied (Daniel et al., 1985 ; Gardner, 1993 ; Stott & Almond, 1995) . Several strategies for vaccination against AIDS have been rigorously evaluated in this model for their efficacy against live virus challenge (Schultz & Stott, 1994 ; Stott, 1994 ; Heeney, 1996) . However, a major limitation of the macaque model is that SIV is antigenically distinct from human immunodeficiency virus types 1 and 2 (HIV-1, HIV-2) and is, therefore, not an appropriate challenge virus for human vaccines currently in phase I and II clinical trials. Therefore, alternative models have been sought.
Several candidate HIV vaccines have been successfully tested for efficacy against HIV-1 in the chimpanzee model (Berman et al., 1990 ; Bruck et al., 1994 ; Girard et al., 1991 Girard et al., , 1995 Robert-Guroff et al., 1995) . However, the model has a number of significant drawbacks. The virus replicates only to low levels and rarely induces disease. The animals are expensive and their use is ethically sensitive. The cost of titrating challenge viruses has limited the number available and most are derived from highly T-cell-adapted atypical strains of HIV-1. Attempts to infect other animal species with HIV-1 have had limited success. Early reports that the pig-tail macaque, Macaca nemestrina, is susceptible to HIV infection have not proved to be generally applicable to a wide range of HIV-1 isolates (Agy et al., 1992) .
The discovery by Shibata et al. (1991) that the env, tat and rev genes of SIV could be replaced by those of HIV-1 and that the resulting chimeric virus, SHIV, retains the ability to infect macaques (Sakuragi et al., 1992 ; Li et al., 1992) was a major breakthrough. The first SHIV chimeras to be constructed were based on HIV-1 envelopes from T-cell-adapted viruses, replicated relatively poorly in vivo and did not induce disease. More recently, a variety of SHIV chimeras has been produced incorporating envelope genes from a wider variety of low passaged HIV-1 isolates (Luciw et al., 1995 ; Dunn et al., 1996 ; Reimann et al., 1996) . Some of these chimeras replicate to higher titres in vivo and are pathogenic. Thus, the SHIV chimeras in macaques provide a highly versatile and adaptable model in which potentially a wide variety of HIV-1 recombinant envelope vaccines may be evaluated against homologous and heterologous challenge viruses for inter-and intra-clade cross-protection. Furthermore, SHIV chimeras potentially permit evaluation of not only the breadth of protection, but also the potency because vaccinated animals can be challenged with chimeras of increasing virulence.
Most of the candidate HIV-1 recombinant envelope vaccines which have so far been tested for efficacy in chimpanzees and macaques have been derived from strains of virus highly adapted to growth in T-cell lines and therefore predominantly using the fusin or CXCR-4 co-receptor. In several instances, such vaccines have been shown to protect effectively against infection (Berman et al., 1990 ; Bruck et al., 1994 ; Robert-Guroff et al., 1995 ; Lu et al., 1996 ; Girard et al., 1991) . However, recent observations (Liu et al., 1996) indicating that individuals who are homozygous for a defect in the CCKR-5 receptor resist multiple exposures to HIV-1 strongly suggest that this co-receptor is essential for initiation of infection in vivo by most strains of HIV-1, though there may be exceptions (Biti et al., 1997) . Therefore, recombinant envelope vaccines based on viruses using this receptor are likely to be more relevant in protection against HIV-1 infection. We have, therefore, tested a recombinant gp120 (W61D) which has been shown to inhibit binding of MIP1β to CCKR-5 (Trkola et al., 1996) , unlike gp120 derived from LAI or MN strains of HIV-1. Furthermore, we have challenged vaccinated animals with a SHIV chimera which expresses the envelope protein of a heterologous clade B San Francisco isolate, HIV-1 SF$$ , and which replicates to high titres and causes CD4 decline in macaques (Luciw et al., 1995) .
Methods
Animals. The study group comprised seven juvenile cynomolgus macaques which were purpose bred in Europe. The animals were housed and maintained in accordance with Home Office guidelines for the care and maintenance of primates. Animals were sedated with Ketamine before vaccination or venepuncture and were examined clinically while under anaesthesia.
Vaccine and challenge virus. The antigen was recombinant gp120 expressed from W61D, an envelope molecular clone from the infectious molecular clone ACH320.3.1 derived from a Dutch HIV-1 isolate (Groenink et al., 1992) . The recombinant protein was produced in a mammalian expression system [chinese hamster ovary (CHO) cells] and was purified by conventional chromatographic techniques including ion exchange, hydrophobic interactions and ultrafiltration. The vaccine consisted of a 1 ml dose containing 100 µg of gp120 in SBN1 adjuvant consisting of an emulsion (SB26) mixed with the monophosphoryl Lipid A and QS21 (a purified saponin). The control animals were given SBN1 adjuvant without antigen.
The challenge virus was SHIV SF$$ , a chimeric virus in which the env, tat and rev genes of the molecular clone SIVmac239 were replaced by those of the San Francisco isolate HIV-1 SF$$ (Luciw et al., 1995) . The virus was grown in simian peripheral blood mononuclear cells (PBMC) and by titration in vivo in rhesus macaques, and had an end-point titre of 10( MID &! . Subsequent titration of this virus stock in cynomolgus macaques gave an end-point titre of 10$ MID &! and the challenge dose of 50 MID &! used in this experiment was based on the titration in cynomolgus macaques.
Plan of study. Four macaques, M186-189, were injected intramuscularly with gp120 in adjuvant at 0, 4 and 87 weeks. Three control macaques, M191-193, were injected with adjuvant alone at the same times. Four weeks after the last injection all seven animals were challenged with 50 MID &! of SHIV SF$$ intravenously. Eight weeks later the animals were killed and their lymphoid tissues were examined for evidence of virus.
Antibody assays. Binding antibodies were detected by either ELISA or immunoblotting. ELISA was performed in microtitre plates coated overnight with either recombinant protein in 50 mM sodium borate or lysates of virus-infected cells. Binding antibodies were detected by affinity-purified goat anti-human IgG, coupled to horseradish peroxidase as previously described (Stott et al., 1990) . The recombinant proteins consisted of the HIV-1 envelope proteins W61D gp120 or SF33 gp120 (kindly provided by Chiron Biocine, Emeryville, Calif., USA) or SIV p27. The cell lysate consisted of rabbit kidney (RK13) cells infected with recombinant vaccinia virus expressing the gp160 of W61D.
The avidity of ELISA antibody to W61D or SF33 gp120 was measured by titration of sera in the presence and absence of 35 mM diethylamine (DEA). Absorbance values were plotted against log "! serum dilution and the slope of the linear part of the curve was calculated to obtain an end-point titre at A 0n1. The avidity index was calculated as the titre in the presence of DEA expressed as a percentage of the titre without DEA (Hedman & Rousseau, 1989) .
Immunoblotting was performed using lysates of C8166 cells either uninfected or infected with SHIV SF$$ as antigens. Antigens were separated by electrophoresis on 12n5 % polyacrylamide gels, transferred to nitrocellulose Hybond-C Extra (Amersham RPN203E) and probed with simian plasma. Binding antibodies were detected with affinitypurified goat anti-human IgG coupled to alkaline phosphatase (Bio-Rad 170-6521) and BCIP\NBT (Sigma B5655) as substrate.
Neutralizing antibodies were measured against HIV-1 W'"D and SHIV SF$$ in a microtitre assay. Serial twofold dilutions of heat-inactivated (56 mC for 1 h) macaque serum were mixed in duplicate with 4-8 TCID &! of virus. After 90 min at room temperature, 5i10% C8166 cells in 200 µl of RPMI medium supplemented with 10 % heat-inactivated FCS, 100 units\ml penicillin and 100 µg\ml streptomycin were added per well. Medium was replaced on days 3, 6 and 8 and virus growth was measured by p27 antigen ELISA on day 10. Neutralization end-point titres were expressed as the log "! reciprocal of the highest dilution of antibody in the serum\virus mixture which showed 75 % inhibition of mean p27 antigen production in the challenge virus controls (Kent et al., 1994) .
Cellular immunity assays. The proliferative responses of fresh
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PBMC from the macaques were measured after the first, second and third doses of vaccine. Blood was collected into preservative-free heparin and the PBMC were separated on Percoll gradients. Freshly isolated PBMC (10& cells) were cultured with antigen in 200 µl of RPMI medium supplemented with 8 % FCS and 10 −% M 2-mercaptoethanol in 96-well plates. The antigens tested were recombinant proteins of SIV gp140 and p27, HIV-1 W'"D gp120 and HIV-1 HXB# p27 and formalin-inactivated SIV. The SIV and HIV recombinant proteins were bound to latex beads (Katrak et al., 1992) at a concentration of 5 µg\ml. In addition, phytohaemagglutinin (PHA) at 100 µg\ml was used as a positive control. Cultures were incubated for 5 days at 37 mC in 5% CO # and pulsed for the last 4-6 h with 0n5 Cytotoxic T-cell activity was measured 5 weeks before and 6 weeks after challenge with SHIV SF$$ . Freshly isolated PBMC were restimulated in vitro in bulk cultures as previously described (Gotch et al., 1991) . Briefly, one-tenth of the fresh autologous PBMC were stimulated with PHA (10 µg\ml) for 12-24 h. These autologous PHA blasts were infected with either HIV-1 W'"D or SIV pJ5 for 1 h, washed and then added back to the remaining cells which had been maintained at 1i10' cells\ml in RPMI supplemented with 8 % FCS and 10 −% M 2-mercaptoethanol at 37 mC in 5% CO # . Target Detection of virus following challenge. Evidence of virus infection in the macaques after challenge was based on the recovery of virus by cocultivation of PBMC and the detection of proviral DNA.
At 2 and 4 weeks after challenge, virus load in the blood was measured by cocultivating dilutions of PBMC containing between 5i10' and 10# cells with C8166 or CEMx174 cells. Following postmortem at 8 weeks after challenge, 5i10' cells from peripheral blood, spleen, mesenteric or peripheral lymph nodes were cocultivated with indicator cells. Cultures were maintained for 28 days and virus was detected by the appearance of syncytia and confirmed with a p27 antigen capture assay (Rose et al., 1995) .
Proviral DNA was detected in PBMC and tissues by specific amplification of either SIV gag or HIV-1 env sequences using a nested PCR and DNA equivalent to 10& cells by methods and primers previously described (Rose et al., 1995 ; Bootman & Kitchin, 1992) .
Results
Antibody responses to vaccination
The four vaccinated macaques, M186-189, made significant antibody responses to both the first and second vaccinations, reaching log "! titres between 4n0 and 4n6 by week 6 (Fig. 1) . During the subsequent rest period there was a sharp decline of between 10-and 40-fold in antibody titres. Thereafter a residual titre of between 2n6 and 3n0 log "! was maintained. Following the third vaccination at week 87, all four animals showed a rise in antibodies to levels equivalent to or greater that those at week 6. On the day of challenge (week 91) titres ranged from log "! 4n0 in M186 to log "! 4n6 in M187. The avidity of the vaccine-induced antibody against W61D gp120 was measured during the course of immunization. Two weeks after the second dose of vaccine (week 6) the avidity index ranged from 69 % to 88 % and the values were similar on the day of challenge 85 weeks later, despite a decrease in M189 at week 70 (Table 1) .
The ability of the vaccine-induced antibodies to bind to recombinant gp120 derived from SF33 (the surface glycoprotein of the challenge virus) was also measured by ELISA. A similar pattern of reactivity was observed, although titres were four-to tenfold lower (Table 1) . However, the avidity indices against W61D and SF33 gp120 were remarkably similar on the day of challenge (week 91).
Further evidence for the presence of binding antibodies to the envelope of the challenge virus SHIV SF$$ was provided by immunoblotting (Fig. 2) . Sera taken from the four vaccinated animals, M186-189, on the day of challenge clearly bound to gp160 and gp120.
The biological activity of the vaccine-induced antibody against HIV-1 W'"D (from which the vaccine was derived) and against SHIV SF$$ (the challenge virus) was measured in neutralization assays (Table 2) . Neither of these two viruses was neutralized by pre-immune sera taken at week 0, but by 2 weeks after the second dose of vaccine, antibody titres against HIV-1 W'"D ranged from 2n1 to 2n5 log "! . Low titres of neutralizing antibodies against SHIV SF$$ were detected in three of the four vaccinated animals. By week 87 (the day of the third vaccination) low levels of neutralizing activity against HIV-1 W'"D could be detected in only three of the four vaccinates. However, on the day of challenge following the third dose of vaccine, neutralizing antibody titres were 2n8-3n9 log "! against HIV-1 W'"D and 2n2-2n7 log "! against SHIV SF$$ .
Cellular responses to vaccination
Lymphocyte proliferation measured 2 weeks after the second dose of vaccine showed a significant response against HIV gp120 in the four vaccinated animals, M186-189, with stimulation indices between 3n0 and 4n7 (Table 3 ). The three control animals, M191-193, showed no response to this antigen and none of the animals showed significant responses to SIV gp120 or to the Gag proteins of SIV or HIV-1 (data not shown). All seven animals had significant responses to PHA with stimulation indices ranging between 6n5 and 24n0. Twenty-one weeks later, specific responses to W61D gp120 were still detectable in three of the four vaccinates (M187-189) 2 n 1 1 n 3 1 n 0 1 n 0 2 n 8 2 n 7 2 n 5 1n5 M187 1n0 1n0 2 n 5 1 n 0 1 n 6 1 n 0 3 n 9 2 n 7 3 n 0 2n2 M188 1n0 1n0 2 n 5 1 n 2 1 n 0 1 n 0 3 n 3 2 n 4 2 n 5 2n2 M189 1n0 1n0 2 n 1 1 n 0 1 n 6 1 n 0 3 n 6 2 n 2 3 n 1 2n1 
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Table 3. Lymphocyte proliferation after vaccination shown by stimulation indices
Con, Negative control of uncoated latex bead ; Env, latex bead coated with W61D gp120 ; PHA, phytohaemagglutinin.
Post first vaccination*
Post second vaccination † Post third vaccination ‡ Macaque Con Env PHA Con Env PHA Con Env PHA M186 2n7 3n4 2 9 n 0 1n2 4 n5 1 5 n 2 2 n 2 6 n 3 43n7 M187 1n8 2n7 2 6 n 4 1n0 4 n7 6 n 5 0 n 8 4 n 2 13n0 M188 1n1 2n7 2 3 n 5 1n6 3 n0 1 0 n 8 1 n 1 5 n 4 159n9 M189 2n0 3n2 5 2 n 3 1n2 3 n1 1 7 n 6 1 n 4 2 n 6 47n3 M191 1n3 1n7 4 0 n 4 1n0 1 n0 1 2 n 8 1 n 1 0 n 8 208n6 M192 2n7 0n7 144n6 1n7 1 n1 1 9 n 1 1 n 1 0 n 9 345n4 M193 1n3 1n9 5 2 n 4 1n4 1 n4 2 4 n 0 0 n 8 0 n 4 127n8
* Four weeks after first vaccination (Week 4). † Two weeks after second vaccination (Week 6). ‡ Four weeks after third vaccination, day of challenge (Week 91).
(data not shown). Proliferation assays at 4 weeks after the final dose of the vaccine, on the day of challenge, indicated that the four vaccinates had stimulation indices between 2n6 and 6n3 in response to gp120 (Table 3) . Cytotoxic T-cell activity was measured 2 weeks after the third dose of vaccine and 6 weeks after the challenge on the three vaccinated animals from which B-cell lines were available (M186-188). A high spontaneous release of &"Cr (up to 50 %) prevented the detection of significant specific release which would indicate induction of CTL. However, the results suggested that a low level of specific lysis of target cells infected with recombinant vaccinia virus expressing the envelope gp160 of W61D was detectable in M187 (12 %) and M188 (5 %) before challenge, but no significant lysis was detectable in M186 at an effector to target ratio of 50 : 1 (data not shown). Six weeks after challenge there was no evidence of significant lysis by lymphocytes from the three vaccinated animals tested (M186-188).
Response to challenge with SHIV SF33
Virus was isolated from all seven animals after challenge with SHIV SF$$ . The virus burden at 2 weeks after challenge ranged from 3 to 3200 positive lymphocytes per million in the 
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vaccinated animals and 32 to 320 positive lymphocytes per million in the three control animals. At 4 weeks the burdens were 0n2 to 32 for vaccinates and 10 to 320 for the controls (Table 4 ). There was, thus, no statistically significant difference between the two groups of animals. Following post-mortem at 8 weeks after challenge, virus was recovered from 11 of the 12 samples taken from the control animals and only seven of the 16 samples taken from vaccinated animals. Proviral DNA was detected by PCR in every sample taken at 2, 4 and 8 weeks after challenge with the exceptions of the PBMC collected from M187 at 4 weeks, and spleen of M193 post-mortem. There was no increase in ELISA antibody to W61D gp120 in the four vaccinates M186-189 following challenge (Figs 1  and 4 ). More surprisingly, the three control animals failed to show any response to this antigen. In contrast, all seven animals generated antibody to SIV p27, although this was very low in three of the four vaccinates (Fig. 3) . Although the three control animals M191-193 showed no response to the recombinant gp120 of W61D, there were significant responses against recombinant gp120 of SF33 (Fig. 4) . Furthermore, analysis of the avidity of the antibodies showed that whereas the avidity of antibodies to SF33 gp120 increased after challenge, the avidity indices to W61D showed a striking decline in all four vaccinates (Fig. 4) .
The neutralizing antibody responses to the challenge showed a decline in titre against HIV-1 W'"D and SHIV SF$$ for the four vaccinated animals between the day of challenge and 8 weeks later. Two of the three control animals, M192 and 193, showed a fourfold increase in titre against SHIV SF$$ , but no significant change against HIV-1 W'"D (Table 2) .
The only significant change in binding antibodies detected by immunoblot after challenge was the acquisition of antibody to p27. This was less marked in vaccinates M186 and 188 than in the remaining animals.
Discussion
A variety of recombinant envelope proteins produced in mammalian, insect and yeast cell systems has been evaluated in phase I and II trials in human volunteers (Walker & Fast, 1994) . These studies have shown that such products are safe and immunogenic, generating significant antibody responses. However, antibodies were short-lived and had little or no neutralizing activity against primary isolates of HIV. Cytotoxic T-cell responses were rarely detected, unless individuals were primed with replicating vectors such as vaccinia virus before immunization with recombinant envelope proteins. The efficacy of some of these products has been evaluated in small numbers of chimpanzees against an in vivo challenge, usually HIV-1 LAI isolate which is highly adapted by passage in continuous human T-cell lines. Chimpanzees have been protected against infection by such vaccination on several occasions (Berman et al., 1990 ; Girard et al., 1991 ; Bruck et al., 1994) . Vaccine cross-protection has also been observed against a heterologous HIV-1 SF# challenge (Girard et al., 1995 ; Berman et al., 1996) . However, these experiments have been criticized because small numbers of animals were used and because the virus replicates poorly in the host and rarely produces disease. Furthermore, there are significant numbers of similarly immunized chimpanzees which have not been protected against challenge (Warren & Levinson, 1995) .
In contrast, in the macaque model vaccination with recombinant proteins without priming with a replicating vector has invariably failed to protect against infection with SIV (Mills et al., , 1993 Giavedoni et al., 1993 ; Silvera et al., 1994) . Even when animals were primed with live recombinant vaccinia vectors expressing envelope protein, protection was only observed when the challenge virus was closely matched genetically to the recombinant vaccine (Hu et al., 1992) . In most other cases animals became infected, although a significant reduction in virus load could sometimes be observed (Ahmed et al., 1994 ; Daniel et al., 1994 ; Israel et al., 1994) .
In the light of these conflicting results between the chimpanzee and macaque models on the efficacy of recombinant envelope proteins as vaccines and in the absence of any clear in vitro correlates of in vivo protection, it is important to evaluate candidate human vaccines in alternative model systems. In the past this was a major limitation of the macaque model since macaques, with the possible exception of Macaca nemestrina (Agy et al., 1992) are not susceptible to HIV-1. However, the finding that chimeric viruses expressing HIV-1 envelope proteins are still capable of infecting and replicating in macaques has provided an alternative system in which candidate HIV-1 vaccines can be evaluated for their efficacy. Furthermore, the envelope expressed can be selected to mimic the envelope of viruses circulating in the target population. Hence, in the experiment we describe, a candidate HIV-1 vaccine currently in clinical trials in the UK and based on a European isolate belonging to the B genotype was tested for ECJ efficacy against a SHIV chimera expressing the envelope of a clade B isolate circulating in North America. A particular attraction of this SHIV SF$$ construct is that it is capable of inducing virus loads which are similar to those induced by SIV and HIV-1 in their respective hosts.
The vaccine used in this experiment was clearly potent. High levels of binding and neutralizing antibodies were detected against the vaccine and its parent virus. Furthermore, these neutralizing antibodies were active against the challenge virus when assayed in a human T-cell line. The antibodies were not tested in primary simian T-cells in which neutralization might be less effective. However, there is no evidence that primary cell assays correlate more closely with in vivo protection. The vaccinated animals also showed T-helper cell proliferative responses against the immunogen, but there was little or no significant cytotoxic T-cell activity detected after vaccination. However, following challenge there was no evidence that the vaccination and the immune responses which it induced had any significant effect on virus replication and dissemination in the lymphoid tissues. M186 had the lowest virus loads in the PBMC at 2 and 4 weeks after challenge. This was also the only animal whose lymph nodes did not yield virus. The reason for the low virus replication in this animal could be individual variation in susceptibility, or the result of immune responses to vaccination. The latter seems unlikely since this animal did not have the highest levels of antibodies, nor the highest stimulation indices.
The failure of a potent vaccine which induces significant immune responses to affect significantly the replication of an SIV-HIV-1 chimeric virus is disappointing and contrasts with previously reported results in both chimpanzees and macaques where the challenge virus was HIV or SHIV carrying the envelope of LAI\IIIB (Berman et al., 1990 ; Girard et al., 1991 ; Bruck et al., 1994 ; Lu et al., 1996 ; Letvin et al., 1997) . Two possible explanations for these conflicting results are, first, the significant antigenic and genetic difference between W61D and SF33 envelope proteins and, secondly, the greater pathogenicity and in vivo replicative capacity of SHIV SF$$ in cynomolgus macaques. A third possibility is that CTL are required, alone or in addition to antibodies to ensure protection against a SHIV chimera ( Letvin et al., 1997) .
The antigenic differences between the envelope proteins of W61D and SF33 are clearly indicated by our data. Although on the day of challenge antibodies from all four vaccinated macaques neutralized both HIV-1 W'"D and SHIV SF$$, the mean titres were almost tenfold higher against HIV-1 W'"D (log "! 3n4) compared with SHIV SF$$ (log "! 2n5). The differences are equally striking when ELISA antibodies are analysed. Titres against W61D gp120 were between log "! 4n0 and 4n9 (mean 4n5), whereas titres against SF33 gp120 were log "! 3n1-4n0 (mean 3n4) (Fig. 4 and Table 1 ). This antigenic distinctiveness was demonstrated in a reciprocal fashion by the control animals infected with SHIV SF$$ , which showed a significant response to gp120 of SF33, but no detectable response against W61D (Fig. 4) . Further evidence for antigenic divergence was revealed by avidity of antibody in the four vaccinated macaques after challenge. Avidity indices increased against SF33 gp120 and decreased against W61D gp120 (Fig. 4) .
Comparison of the predicted amino acid sequences of the gp120 of W61D and SF33 revealed 88 % similarity and 82 % identity between the two proteins. This degree of genetic diversity is within the range currently found among the HIV-1 clade B isolates currently circulating in the population, but may represent two extremes of the spectrum. If, however, this reflects sufficient antigenic diversity to prevent cross-protection by envelope-based vaccines, their efficacy in man is likely to be severely restricted. This question will to some extent be resolved when similarly vaccinated animals are challenged with a genetically matched SHIV W'"D which we have constructed recently (Ranjbar et al., 1997) . Further experiments with divergent pathogenic SHIV carrying other gp120 sequences will be needed to establish fully if protection is type specific or group specific.
The replicative capacities of SHIV SF$$ , SHIV )* n 'p and SHIV SBG (Luciw et al., 1995 ; Dunn et al., 1996 ; Reimann et al., 1996) are clearly greater than the original SHIV NM and SHIV-4 (Shibata et al., 1991 ; Li et al., 1992) . However, it is difficult to evaluate how far this factor was responsible for the failure of the W61D vaccine to prevent infection with SHIV SF$$ in our experiment. A challenge with SHIV-4 might have been prevented by this vaccine, despite its genetic divergence from W61D. If this were to be the case, then the question arises as to which challenge virus more closely resembles HIV-1 infection in humans. This will, ultimately, only be resolved when phase III vaccine trials of candidate recombinant envelope vaccines are conducted. However, on the currently available data it would appear that the chimeric viruses with a higher replicative capacity and increased pathogenicity more closely resemble the infection with SIV in macaques or HIV-1 in humans.
A novel aspect of the W61D gp120 vaccine is that this protein inhibits the binding of MIP1β to the co-receptor CCKR-5, unlike gp120 derived from LAI and MN isolates (Trkola et al., 1996) . The recent observations that individuals which are homozyous for a 32-base-pair deletion in this secondary receptor are resistant to infection with HIV despite multiple exposures strongly suggests that this co-receptor is essential for the initiation of infection in vivo by most strains of HIV-1 and, therefore, that viruses which can use this coreceptor are also most likely to initiate infection. If this proves to be the case, then envelope proteins and challenge viruses which use this receptor are likely to be more relevant in the prevention of HIV-1 infection.
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